The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q ; day:14 ; month:12 ; year:2018 ; pages:1-8
PharmacoEconomics - open ; (14.12.2018), 1-8
- Creator
-
Lee, Dawn
Brereton, Nic
Dhanasiri, Sujith
Kulasekararaj, Austin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-018-0110-3
- URN
-
urn:nbn:de:101:1-2019013123323565778175
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Dawn
- Brereton, Nic
- Dhanasiri, Sujith
- Kulasekararaj, Austin
- SpringerLink (Online service)
Other Objects (12)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Charakterisierung der 5q-Deletion beim Prostatakarzinom
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Charakterisierung der 5q-Deletion beim Prostatakarzinom
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide